A rationally designed probiotic platform targeting the gut–lung axis to reduce intestinal and pulmonary inflammation in people with cystic fibrosis, COPD, and asthma.
Millions of people with CF, COPD, and asthma experience gut dysbiosis and chronic pulmonary inflammation that current treatments do not adequately address.
65% experience chronic GI symptoms independent of existing therapies. Even people on CFTR modulators retain significant gut dysbiosis and residual pulmonary inflammation.
The fourth leading cause of death globally. Gut dysbiosis is increasingly recognized as a feature of chronic airway inflammation in COPD, yet no approved therapy targets the gut-lung connection.
Asthma affects 1 in 13 people in the US. Emerging evidence links gut microbial imbalance to airway immune dysregulation, pointing to the gut-lung axis as a therapeutic opportunity.
Axoguard 01 is a rationally designed cocktail of three clinically selected bacterial strains, adapted specifically to survive and function in the gut environment of people with chronic airway disease.
Combined with an optimized prebiotic formulation, it maximizes immune-modulatory metabolite output where generic probiotics fall short. As an oral dietary supplement, it offers a faster and more accessible path to people than a traditional drug development program.
Axoguard 01 is designed to complement existing therapies such as CFTR modulators, addressing the residual gut dysbiosis they do not correct.
We are actively seeking collaborators, clinical partners, and investors to advance Axoguard 01 toward clinical evaluation in people with CF, COPD, and asthma.
rebecca@axobiome.com